An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

This is an open-label extension study for participants who were previously enrolled in and completed an Avalyn Pharma Sponsored study with an inhaled antifibrotic, such as AP01. Eligible participants will have their final dose of drug at the end of study visit from the lead-in study and first AP-LTE-008 study visit on the same day.

NCT Number	NCT06951217
Lead Sponsor	Avalyn Pharma Inc.
Conditions	Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Enrollment	340 participants
Start Date	2025-04-17
Primary Completion	2031-12-31 (estimated)
Study Completion	2031-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-07